Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.37, $0.01 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $23.4 million versus the consensus estimate of $23.89 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.